Identifying immune signatures could refine patient selection and surgical outcomes for those with MEN1-related neuroendocrine tumors.

• Analyzed 42 MEN1 patients with duodenopancreatic neuroendocrine tumors (DPNETs); 14 had liver metastasis.
• Identified 1,117 immunoglobulin-bound proteins; 435 antigens enriched in DPNET patients, with 130 higher in those with liver metastasis.

Surgeons may consider these findings for better risk stratification and individualized surgical approaches in treating MEN1.

• Networks indicated potential targets for immunotherapy based on B- and T-cell signaling pathways.